Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
13 listopada 2017 zaktualizowane przez: GlaxoSmithKline
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.
This protocol posting has been updated for sections impacted by the Protocol amendment 1, Sept 2009.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Szczegółowy opis
Collaborators: United States Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
1343
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
British Columbia
-
Surrey, British Columbia, Kanada, V3R 8P8
- GSK Investigational Site
-
-
Nova Scotia
-
Truro, Nova Scotia, Kanada, B2N 1L2
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Kanada, M9W 4L6
- GSK Investigational Site
-
-
Quebec
-
Pointe-Claire, Quebec, Kanada, H9R 4S3
- GSK Investigational Site
-
-
-
-
Alabama
-
Huntsville, Alabama, Stany Zjednoczone, 35802
- GSK Investigational Site
-
-
Florida
-
Jacksonville, Florida, Stany Zjednoczone, 32216
- GSK Investigational Site
-
Miami, Florida, Stany Zjednoczone, 33143
- GSK Investigational Site
-
-
Idaho
-
Meridian, Idaho, Stany Zjednoczone, 83642
- GSK Investigational Site
-
-
Kansas
-
Lenexa, Kansas, Stany Zjednoczone, 66219
- GSK Investigational Site
-
-
Montana
-
Missoula, Montana, Stany Zjednoczone, 59801
- GSK Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89104
- GSK Investigational Site
-
-
New Jersey
-
Edison, New Jersey, Stany Zjednoczone, 08817
- GSK Investigational Site
-
-
New York
-
Rochester, New York, Stany Zjednoczone, 14609
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44122
- GSK Investigational Site
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Tak
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Subjects who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject.
- Male and female adults, >= 18 years of age at the time of the first vaccination.
- Safety laboratory test results within the parameters specified in the protocol.
- Satisfactory baseline medical assessment by history and physical examination.
- Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits as documented by signature on the informed consent document.
- Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of first vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion Criteria:
- Medical history of physician-confirmed infection with an A/California/7/2009 (H1N1)v-like virus
- Previous vaccination at any time with an H1N1v-like virus vaccine or a medical history of physician-confirmed infection with an H1N1v-like virus.
- Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
- Presence of a temperature >= 38.0ºC (>=100.4ºF), or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
- Diagnosed with cancer, or treatment for cancer, within 3 years.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed.
- Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period.
- Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination, are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible.
- An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6 weeks of receipt of seasonal influenza vaccine
- With the exception of seasonal influenza vaccination, administration of any vaccine(s) within 30 days before study vaccination on Day 0. Seasonal influenza vaccine may be administered up to 14 days prior to study vaccination on Day 0.
- Planned administration of any vaccine not foreseen by the study protocol between Day 0 and the Day 42 phlebotomy, including seasonal influenza vaccine or a monovalent pandemic H1N1 vaccine other than the study vaccines.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine/product, or planned use during the study period.
- Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.
- Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to the first vaccination.
- Lactating or nursing women.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: GSK2340274A F1_2D Group
Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
|
one or two intramuscular injections
|
|
Eksperymentalny: GSK2340274A F2_2D Group
Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
|
one or two intramuscular injections
|
|
Eksperymentalny: GSK2340274A F2_1D Group
Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
|
one or two intramuscular injections
One injection
|
|
Eksperymentalny: GSK2340274A F1_1D Group
Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
|
one or two intramuscular injections
One injection
|
|
Eksperymentalny: GSK2340273A F1_1D Group
Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
|
One injection
one or two intramuscular injections
|
|
Eksperymentalny: GSK2340273A F2_2D Group
Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
|
one or two intramuscular injections
|
|
Eksperymentalny: GSK2340273A F2_1D Group
Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
Subjects above (>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm.
|
One injection
one or two intramuscular injections
|
|
Eksperymentalny: GSK2340273A F3_2D Group
Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
|
one or two intramuscular injections
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain
Ramy czasowe: At Day 0
|
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and subjects older than (>) 60 years.
|
At Day 0
|
|
Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain
Ramy czasowe: At Day 21
|
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and subjects > 60 years.
|
At Day 21
|
|
Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain
Ramy czasowe: At Day 0
|
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 64 years (y) old and subjects > 64 years.
|
At Day 0
|
|
Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain
Ramy czasowe: At Day 21
|
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 64 years (y) old and subjects > 64 years.
|
At Day 21
|
|
Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 21
|
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18 and 60 years of age and older (>60y).
|
At Day 21
|
|
Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Strain
Ramy czasowe: At Day 21
|
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18 and 64 years and older (>64y).
|
At Day 21
|
|
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 0
|
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) and results were tabulated for subjects between 18 and 60 years and older (>60y).
|
At Day 0
|
|
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 21
|
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
The Flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 60 years and older (>60y).
|
At Day 21
|
|
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain
Ramy czasowe: At Day 0
|
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
The Flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years and older (>64y).
|
At Day 0
|
|
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain
Ramy czasowe: At Day 21
|
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
The Flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years and older (>64y).
|
At Day 21
|
|
Seroconversion Factor (SCF) for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 21
|
SCF was defined as the fold increase in serum HI geometric mean ratio (mean[log10(POST/PRE)]) vaccination compared to Day 21.
The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 60 years of age and older (>60y).
|
At Day 21
|
|
Seroconversion Factor (SCF) for HI Antibodies Against A/California Strain
Ramy czasowe: At Day 21
|
SCF was defined as the fold increase in serum HI geometric mean ratio (mean[log10(POST/PRE)]) vaccination compared to Day 21.
The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years of age and older (>64y).
|
At Day 21
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Days 0 and 21
|
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and > 60 years and subjects between 18 and 64 years old and > 64 years, respectively.
|
At Days 0 and 21
|
|
Titers for HI Antibodies Against A/California Strain
Ramy czasowe: At Days 0 and 21
|
Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and > 60 years and subjects between 18 and 64 years old and > 64 years, respectively.
|
At Days 0 and 21
|
|
Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 21
|
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (>60y) and for subjects between 18-64 years old and >64 years.
|
At Day 21
|
|
Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain
Ramy czasowe: At Days 0 and 21
|
A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (>60y) and for subjects between 18-64 years old and >64 years.
|
At Days 0 and 21
|
|
Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 21
|
SCF was defined as the fold increase in serum HI geometric mean ratio (mean[log10(POST/PRE)]) vaccination compared to Day 21.
The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18-60 years of age and older (> 60y) and for subjects between 18-64 years old and > 64 years.
|
At Day 21
|
|
Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain
Ramy czasowe: At Days 0 and 42
|
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal HI antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and > 60 years and subjects between 18 and 64 years old and > 64 years, respectively.
|
At Days 0 and 42
|
|
Titers for HI Antibodies Against the A/California Virus Strain
Ramy czasowe: At Days 0 and 42
|
Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and > 60 years and subjects between 18 and 64 years old and > 64 years, respectively.
|
At Days 0 and 42
|
|
Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 42
|
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (>60y) and for subjects between 18-64 years old and >64 years.
|
At Day 42
|
|
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain
Ramy czasowe: At Days 0 and 42
|
A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (>60y) and for subjects between 18-64 years old and >64 years.
|
At Days 0 and 42
|
|
Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 42
|
SCF was defined as the fold increase in serum HI geometric mean ratio (mean[log10(POST/PRE)]) vaccination compared to Day 21.
The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18-60 years of age and older (> 60y) and for subjects between 18-64 years old and > 64 years.
|
At Day 42
|
|
Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain
Ramy czasowe: At Days 0 and 182
|
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal HI antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and > 60 years and subjects between 18 and 64 years old and > 64 years, respectively.
|
At Days 0 and 182
|
|
Titers for HI Antibodies Against the A/California Virus Strain
Ramy czasowe: At Days 0 and 182
|
Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10.
Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and > 60 years and subjects between 18 and 64 years old and > 64 years, respectively.
|
At Days 0 and 182
|
|
Number of Seroconverted (SCR) Subjects for HI Antibodies
Ramy czasowe: At Day 182
|
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (>60y) and for subjects between 18-64 years old and >64 years.
|
At Day 182
|
|
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Days 0 and 182
|
A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40.
The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (>60y) and for subjects between 18-64 years old and >64 years.
|
At Days 0 and 182
|
|
Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain
Ramy czasowe: At Day 182
|
SCF was defined as the fold increase in serum HI geometric mean ratio (mean[log10(POST/PRE)]) vaccination compared to Day 21.
The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18-60 years of age and older (> 60y) and for subjects between 18-64 years old and > 64 years.
|
At Day 182
|
|
Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain
Ramy czasowe: At Day 21
|
Titers were presented as geometric mean titers (GMTs).
Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, > 60 years, 18-64 years and > 64 years, from the pooled group GSK2340274A F1 and GSK2340273A F3_2D Group.
|
At Day 21
|
|
Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain
Ramy czasowe: At Day 21
|
Titers were presented as geometric mean titers (GMTs).
Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, > 60 years, 18-64 years and > 64 years, from the pooled groups GSK2340274A F1 and GSK2340273A F2.
|
At Day 21
|
|
Adjusted GMT Ratios of A/California Virus Strain
Ramy czasowe: At Day 21
|
Titers were presented as geometric mean titers (GMTs).
Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, > 60 years, 18-64 years and > 64 years, from the pooled group GSK2340274A F1 and the GSK2340273A F1_1D Group.
|
At Day 21
|
|
Adjusted GMT Ratios of A/California Strain
Ramy czasowe: At Day 21
|
Titers were presented as geometric mean titers (GMTs).
Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, > 60 years, 18-64 years and > 64 years, from the pooled group GSK2340274A F2 and the GSK2340273A F3_2D Group.
|
At Day 21
|
|
Adjusted GMT Ratios for A/California Virus Strain
Ramy czasowe: At Day 21
|
Titers were presented as geometric mean titers (GMTs).
Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, > 60 years, 18-64 years and > 64 years, from the pooled groups GSK2340274A F2 and GSK2340273A F2.
|
At Day 21
|
|
Adjusted GMT Ratios for A/California Strain
Ramy czasowe: At Day 21
|
Titers were presented as geometric mean titers (GMTs).
Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, > 60 years, 18-64 years and > 64 years, from the pooled group GSK2340274A F2 and the GSK2340273A F1_1D Group.
|
At Day 21
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Ramy czasowe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activities as assessed by inability to attend/do work or school.
Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
|
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Ramy czasowe: During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects > 64 years of age
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activities as assessed by inability to attend/do work or school.
Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
|
During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects > 64 years of age
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Ramy czasowe: During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age
|
Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)], headache, joint pain at other location, muscle aches, shivering and sweating.
Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider.
Grade 3 fever = fever ≥ 39.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
|
During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Ramy czasowe: During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects > 64 years of age
|
Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)], headache, joint pain at other location, muscle aches, shivering and sweating.
Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider.
Grade 3 fever = fever ≥ 39.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
|
During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects > 64 years of age
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Ramy czasowe: During the 7-day (Days 0-6) post-Dose 3 vaccination period, for subjects > 60 years of age
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activities as assessed by inability to attend/do work or school.
Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Results were tabulated for subjects in GSK2340273A F2_1D Group, who were older than 60 years of age (>60y).
|
During the 7-day (Days 0-6) post-Dose 3 vaccination period, for subjects > 60 years of age
|
|
Number of Subjects With Any and Grade 3 Solicited General Symptoms
Ramy czasowe: During the 7-day (Days 0-6) post-Dose 3 vaccination period, for subjects > 60 years of age
|
Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)], headache, joint pain at other location, muscle aches, shivering and sweating.
Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider.
Grade 3 fever = fever ≥ 39.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
Results were tabulated for subjects in GSK2340273A F2_1D Group, who were older than 60 years of age (>60y).
|
During the 7-day (Days 0-6) post-Dose 3 vaccination period, for subjects > 60 years of age
|
|
Number of Subjects With Abnormal Biochemical and Haematological Levels
Ramy czasowe: At Days 7, 21, 28, 42 and 182, for subjects between 18-64 years of age
|
Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], alkaline phosphatase [AP], aspartate aminotransferase [AST], basophils [BAS], bilirubin [BIL], bilirubin conjugated/direct [BIL/CD] creatinine [CREA], eosinophils [EOS], hematocrit [HEM], haemoglobin [Hgb], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelets [PLA], red blood cells [RBC], blood urea nitrogen [BUN] and white blood cells [WBC]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above the reference range defined for the specified time point and laboratory parameter. |
At Days 7, 21, 28, 42 and 182, for subjects between 18-64 years of age
|
|
Number of Subjects With Abnormal Biochemical and Haematological Levels
Ramy czasowe: At Days 7, 21, 28, 42 and 182, for subjects > 64 years of age
|
Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], alkaline phosphatase [AP], aspartate aminotransferase [AST], basophils [BAS], bilirubin [BIL], bilirubin conjugated/direct [BIL/CD] creatinine [CREA], eosinophils [EOS], hematocrit [HEM], haemoglobin [Hgb], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelets [PLA], red blood cells [RBC], blood urea nitrogen [BUN] and white blood cells [WBC].
Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above the reference range defined for the specified time point and laboratory parameter.
|
At Days 7, 21, 28, 42 and 182, for subjects > 64 years of age
|
|
Number of Subjects With Any Medically-attended Adverse Events (MAEs)
Ramy czasowe: Days 0 to 385
|
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason.
Any was defined as the occurrence of any MAE regardless of intensity grade or relation to vaccination.
Results were tabulated for subjects aged between 18 and 64 years and older (>64y).
|
Days 0 to 385
|
|
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
Ramy czasowe: Days 0 to 365
|
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Results were tabulated for subjects aged between 18-64 years and above 65 years (+65y).
|
Days 0 to 365
|
|
Number of Subjects With Any Unsolicited Adverse Events (AEs)
Ramy czasowe: Within the 42-day (Days 0-41) post-vaccination period
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
Within the 42-day (Days 0-41) post-vaccination period
|
|
Number of Subjects With Any Unsolicited Adverse Events (AEs)
Ramy czasowe: Within the 84-day (Days 0-83) post-vaccination period
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Results were tabulated for subjects aged between 18-64 years and older (>64y).
|
Within the 84-day (Days 0-83) post-vaccination period
|
|
Number of Subjects With Serious Adverse Events (SAEs)
Ramy czasowe: During the entire study period (from Day 0 to Day 385)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Results were tabulated for subjects aged between 18-64 years and older (>64y).
|
During the entire study period (from Day 0 to Day 385)
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
11 października 2009
Zakończenie podstawowe (Rzeczywisty)
9 listopada 2009
Ukończenie studiów (Rzeczywisty)
16 grudnia 2010
Daty rejestracji na studia
Pierwszy przesłany
24 września 2009
Pierwszy przesłany, który spełnia kryteria kontroli jakości
24 września 2009
Pierwszy wysłany (Oszacować)
28 września 2009
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
12 grudnia 2017
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
13 listopada 2017
Ostatnia weryfikacja
1 listopada 2017
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 113440
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
TAK
Opis planu IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Badanie danych/dokumentów
-
Protokół badania
Identyfikator informacji: 113440Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan analizy statystycznej
Identyfikator informacji: 113440Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz świadomej zgody
Identyfikator informacji: 113440Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz zgłoszenia przypadku z adnotacjami
Identyfikator informacji: 113440Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Raport z badania klinicznego
Identyfikator informacji: 113440Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Specyfikacja zestawu danych
Identyfikator informacji: 113440Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Indywidualny zestaw danych uczestnika
Identyfikator informacji: 113440Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .